Not Signed In - Human Genome Sciences Initiates Phase 3 Clinical Trial Of Albuferon(R) With Ribavirin In Patients With Chronic Hepatitis C Genotypes 2 And 3
Wed, 28 Feb 2007 08:00 AM EST
... Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has initiated dosing in ACHIEVE 2/3, a Phase 3 clinical trial of Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in treatment-naive patients with chronic hepatitis C genotypes 2 and 3. [click link for full article] ...
Related Topics
- Clinical Trials
- Genes and Gene Therapy
- Hepatitis C
- Hepatitis B
- Hepatitis A
- Psychopharmacology
- Hepatitis
- Autoimmune Hepatitis
- Human Genome Epidemiology Network
- Hepatitis A and Hepatitis B Vaccine
- Hepatitis A Vaccine
- Hepatitis B Vaccine
- Chronic Fatigue Syndrome
- Hepatitis B Immune Globulin
- Pain - Chronic
- Chronic Pain
- Human Papilloma Virus
- Chronic Diseases
- Chronic Hepatitis C: Current Disease Management
- Pharmacology
email this page
print this page
bookmark this page
feedback on this page
